Advancing Care through Innovation

Clinical Trials
at Salma Health

Take Part in the Future of Medicine

Learn more

Be part of something bigger

At Salma Health, we believe everyone deserves access to the latest medical advances.

Our clinics in La Jolla (San Diego) and Laguna Hills (Orange County) are actively enrolling clinical trials in neurology and psychiatry. Whether you're managing a condition or simply want to contribute to the future of medicine, there may be a trial right for you, and we'll guide you every step of the way.

How Clinical Trials Work at Salma Health

Whether you're living with a neurological or psychiatric condition or simply want to contribute to meaningful research, here's what to expect when you get started.
1. Join the Registry
Share a few basic details about yourself and your health interests. It takes minutes, and there's no obligation to continue.
2. Get Matched
We'll reach out to you if a study you may be eligible for is open or coming soon. No searching required.
3. See If You Qualify
Our team walks you through what's involved and answers your questions, so you can confidently decide whether to move forward.
4. Participate at No Cost
All studies are conducted at our clinics to the highest ethical standards. Participation is always free, voluntary, and on your terms.

Active Studies Now Enrolling in California

Browse our currently enrolling studies in neurology and psychiatry. If you don't see one that fits right now, join our registry and we'll notify you when one opens.
Neurology
PHASE 2
MIGRAINE
Join our registry

A New Approach to Migraine Prevention

Sponsor: Ipsen Innovation
|
Drug/Intervention: IPN10200 (next-generation botulinum toxin, injected)
Join our registry
For millions of people, migraines are debilitating and current preventive treatments don’t work for everyone. This Phase 2 study evaluates IPN10200, a next-generation botulinum toxin injected into the muscles of the head and neck, to prevent both episodic and chronic migraine. Unlike BOTOX® (which it builds upon), IPN10200 is engineered for improved localized precision and potentially longer-lasting relief. Participants receive injections in a two-step design and are followed for up to 42 weeks.

‍Site: Salma Health San Diego | 4180 La Jolla Village Dr, Suite 240, La Jolla, CA 92037
ClinicalTrials.gov: NCT06625060
Am I eligible?

• Adults diagnosed with episodic migraine (≥6 migraine days/month) or chronic migraine (≥15 headache days/month, ≥8 of which are migraines)

• Migraine diagnosis for at least 12 months, and onset before age 50

• Have tried at least one preventive migraine medication in the past

• No current uncontrolled psychiatric conditions that could interfere with participation

PHASE 2
ALZHEIMER’S DISEASE
Join our registry

Treating Agitation in Alzheimer’s Disease

Sponsor: Bristol-Myers Squibb (Celgene)
|
Drug/Intervention: BMS-986368 (a FAAH/MGLL Inhibitor)
Join our registry
Agitation is one of the most distressing symptoms of Alzheimer’s disease for both patients and caregivers. BALANCE-AAD-1 is testing a novel oral medication, BMS-986368, which targets the brain’s endocannabinoid system to see if it can safely reduce agitation without the side effects of currently available treatments. This randomized, double-blind, placebo-controlled study is one of the first to target this pathway for behavioral symptoms in Alzheimer’s.

‍Site: Salma Health San Diego | 4180 La Jolla Village Dr, Suite 240, La Jolla, CA 92037
ClinicalTrials.gov: NCT06808984
Am I eligible?

• Adults aged 55-90 with a diagnosis of Alzheimer’s Disease and a history of agitation

• Currently experiencing agitation for at least 4 weeks prior to enrollment

• A mini mental state exam (MMSE) score of <21 at screening visit

• Living at home, in assisted living, or a nursing facility with an available caregiver/study partner

• Stable living situation for at least 8 weeks before the study begins

PHASE 3
ALZHEIMER’S DISEASE
Join our registry

Treating Agitation in Alzheimer’s Disease

Sponsor: Bristol-Myers Squibb
|
Drug/Intervention: KarXT (BMS-986510) and KarX-EC (BMS-986519) 
Join our registry
Agitation is one of the most distressing symptoms of Alzheimer’s disease for both patients and caregivers. ADAGIO-1 is a Phase 3 study testing KarXT + KarX-EC (BMS-986510 + BMS-986519), a novel two-capsule oral regimen that activates M1/M4 muscarinic receptors in the brain through two timed releases of xanomeline — a completely different mechanism from the antipsychotics currently used, which often have limited efficacy and carry safety warnings in older adults with dementia. This randomized, double-blind, placebo-controlled study aims to determine whether KarXT + KarX-EC can safely and effectively reduce agitation in adults with mild to severe Alzheimer's disease.

Site: Salma Health San Diego | 4180 La Jolla Village Dr, Suite 240, La Jolla, CA 92037
ClinicalTrials.gov: NCT07011732
Am I eligible?

• Adults aged 55-90 with a diagnosis of Alzheimer’s Disease and a history of agitation

• Currently experiencing agitation for at least 2 weeks prior to enrollment

• A mini mental state exam (MMSE) score of 5 to 22, inclusive at Screening visit

• Living at home, in assisted living, or a nursing facility with an available caregiver/study partner

• Stable living situation for at least 6 weeks before the study begins

Mood Disorder Trials
PHASE 3
MAJOR DEPRESSIVE DISORDER
Join our registry

A Whole New Mechanism for Depression

Sponsor: Xenon Pharmaceuticals
|
Drug/Intervention: Azetukalner (XEN1101, oral) — a novel KV7 potassium channel opener
Join our registry
Most antidepressants work by modulating serotonin or norepinephrine but they don’t work for everyone, and many come with burdensome side effects like weight gain and sexual dysfunction. Azetukalner takes a completely different approach: it activates KV7 potassium channels in the brain, calming overactive neural circuits associated with depression. After promising Phase 2 results, Xenon is now running this large Phase 3 trial in adults with moderate-to-severe Major Depressive Disorder (MDD).

Site: Salma Health San Diego | 4180 La Jolla Village Dr, Suite 240, La Jolla, CA 92037
ClinicalTrials.gov: NCT07076407
Am I eligible?

• Adults with Major Depressive Disorder (MDD)

• Currently experiencing a moderate-to-severe depressive episode

• Not currently taking or recently discontinued certain antidepressant medications

• No history of psychotic features, bipolar disorder, or active suicidal ideation with a plan

PHASE 3
TREATMENT RESISTANT DEPRESSION
Join our registry

RECOVER: VNS Therapy for Difficult-to-Treat Depression

Sponsor: LivaNova
|
Drug/Intervention: VNS Therapy® (Vagus Nerve Stimulation, an implanted device)
Join our registry
For people who have tried multiple antidepressants without relief, vagus nerve stimulation (VNS) offers a fundamentally different approach. A small, pacemaker-like device is implanted under the collarbone and sends gentle electrical pulses to the vagus nerve, modulating mood-regulating circuits deep in the brain. The RECOVER study is the landmark clinical trial establishing VNS Therapy® as a treatment for treatment-resistant depression (TRD), enrolling patients who have failed at least four antidepressant treatments. Salma Health has been a site since 2022, making us one of the most experienced sites in the country for this therapy.

Site: Salma Health San Diego | 4180 La Jolla Village Dr, Suite 240, La Jolla, CA 92037
ClinicalTrials.gov: NCT03887715
Am I eligible?

• Adults with unipolar or bipolar depression that have not responded to at least 4 prior antidepressant treatments

• Currently experiencing a depressive episode

• Medically eligible for a minor surgical implant procedure

• No prior VNS device implantation

• Willing and able to attend regular follow-up visits

Our track record

Past and completed studies

Our track record reflects our commitment to rigorous science, compassionate patient care and operational excellence. We partner with sponsors to run studies that matter—and with patients to make participation accessible.
Axsome
Biohaven
LivaNova
Noema
Otsuka
Aribio
PrecisionMed
Cognition Therapeutics
Manistee
Axsome
Biohaven
LivaNova
Noema
Otsuka
Aribio
PrecisionMed
Cognition Therapeutics
Manistee
Six Active Studies Now Enrolling

Ready to Be Part of Something Bigger?

Join the Salma Health Patient Registry — your first step toward participating in clinical research that matters.
Get started
Our Programs
Military and VeteransDepression and AnxietyHeadache and Facial PainMemory and DementiaBrain Injuries
About Us
Our StoryOur Clinical TeamOur LocationsLegalCareers
Resources
Why Salma HealthOur BlogConditions We TreatTreatments and Services
Legal
Notice of Privacy PracticesTerms of UsePrivacy PolicyGood Faith Estimate
Account
Appointment Support
Referrals
Refer a Patient
Link to Salma Facebook PageLink to Salma Linkedin PageLink to Salma Instagram Page
Notice of Privacy Practices
Terms of Use
Privacy Policy
Good Faith Estimate

The professional services made available through Salma Health, Inc. are provided by licensed clinicians affiliated with independently owned and operated professional practices, including Center for Neurohealth, Inc., dba Salma Health, Ocean Psychiatry, Inc, and Salma Health LLC. Salma Health, Inc. provides administrative, technology and other related services to the professional practices it supports and does not itself provide any medical, mental health or other healthcare provider services. The content on this website has been reviewed by Center for Neurohealth, Inc., dba Salma Health, Ocean Psychiatry, Inc, and Salma Health LLC. The content on this website is for information purposes only and is not a substitute for professional medical advice, diagnosis or treatment.

© 2026 Salma Health, Inc.